Published in Clin Exp Immunol on March 01, 1995
Toll-like receptor agonists in cancer therapy. Immunotherapy (2009) 1.58
Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guerin (BCG) results in the release of functional soluble TRAIL/Apo-2L. Blood (2005) 1.42
Role of neutrophils in BCG immunotherapy for bladder cancer. Urol Oncol (2008) 1.25
Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancer. Cancer Immun (2007) 1.19
Toll-like receptor agonists: are they good adjuvants? Cancer J (2010) 1.16
Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette-Guérin (BCG) mediated antitumour activity. Clin Exp Immunol (2003) 1.12
Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review. Rheumatol Int (2005) 1.03
Clinical and immune impact of Mycobacterium bovis BCG vaccination scarring. Infect Immun (2002) 1.01
Systemic immune response after intravesical instillation of bacille Calmette-Guérin (BCG) for superficial bladder cancer. Clin Exp Immunol (1999) 0.96
Polarisation of a T-helper cell immune response by activation of dendritic cells with CpG-containing oligonucleotides: a potential therapeutic regime for bladder cancer immunotherapy. Br J Cancer (2003) 0.91
Identification of the mycobacterial subcomponents involved in the release of tumor necrosis factor-related apoptosis-inducing ligand from human neutrophils. Infect Immun (2006) 0.87
Immunotherapy for bladder cancer. Res Rep Urol (2015) 0.86
Immunotherapy for urothelial carcinoma: current status and perspectives. Cancers (Basel) (2011) 0.83
Natural killer cell cytokine response to M. bovis BCG Is associated with inhibited proliferation, increased apoptosis and ultimate depletion of NKp44(+)CD56(bright) cells. PLoS One (2013) 0.83
Immunological basis in the pathogenesis and treatment of bladder cancer. Expert Rev Clin Immunol (2014) 0.83
Sequential intravesical mitomycin plus Bacillus Calmette-Guérin for non-muscle-invasive urothelial bladder carcinoma: translational and phase I clinical trial. Clin Cancer Res (2014) 0.82
Mathematical model of tumor immunotherapy for bladder carcinoma identifies the limitations of the innate immune response. Oncoimmunology (2012) 0.82
Enhancing the immunotherapeutic potential of mycobacteria by transfection with tumour necrosis factor-alpha. Immunology (1999) 0.79
Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer. Bladder Cancer (2016) 0.79
BCG response prediction with cytokine gene variants and bladder cancer: where we are? J Cancer Res Clin Oncol (2011) 0.77
Applications of bacillus Calmette-Guerin and recombinant bacillus Calmette-Guerin in vaccine development and tumor immunotherapy. Expert Rev Vaccines (2015) 0.76
Reactive arthritis following BCG immunotherapy for bladder carcinoma. Clin Rheumatol (2005) 0.75
Novel immunotherapeutic approaches to the treatment of urothelial carcinoma. Ther Adv Urol (2016) 0.75
Nonmuscle invasive bladder cancer: a primer on immunotherapy. Cancer Biol Med (2016) 0.75
The association between CD2+ peripheral blood lymphocyte subsets and the relapse of bladder cancer in prophylactically BCG-treated patients. Br J Cancer (1999) 0.75
Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer. Cancer Immunol Immunother (2016) 0.75
Interstitial cystitis intravesical therapy. Transl Androl Urol (2017) 0.75
IL-10 neutralization augments mouse resistance to systemic Mycobacterium avium infections. J Immunol (1993) 1.87
Growth inhibition of Mycobacterium bovis by IFN-gamma stimulated macrophages: regulation by endogenous tumor necrosis factor-alpha and by IL-10. Int Immunol (1994) 1.68
Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy. J Urol (1990) 1.66
Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol (1992) 1.38
Carcinoma in situ. Urol Clin North Am (1992) 1.27
T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol (1993) 1.24
Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer. Cancer Immunol Immunother (1992) 1.15
Bacillus Calmette-Guérin therapy alters the progression of superficial bladder cancer. J Clin Oncol (1988) 1.11
The plight of the patient with carcinoma in situ of the bladder. J Urol (1970) 1.09
A dual mechanism of immunosuppression by FK-506. Differential suppression of IL-4 and IL-10 levels in T helper 2 cells. Transplantation (1993) 1.05
Carcinoma in situ of the bladder. Cancer (1980) 0.93
Urinary interleukins in patients receiving intravesical Bacillus Calmette-Guerin therapy for superficial bladder cancer. Cancer (1989) 0.93
Murine bladder carcinoma cells present antigen to BCG-specific CD4+ T-cells. Cancer Res (1992) 0.91
Role of adhesion molecules in lymphokine-activated killer cell killing of bladder cancer cells: further evidence for a third ligand for leucocyte function-associated antigen-1. Immunology (1992) 0.91
HLA-DR expression by high grade superficial bladder cancer treated with BCG. Br J Urol (1989) 0.90
The effects of recombinant human interferon-gamma on a panel of human bladder cancer cell lines. J Urol (1991) 0.89
Induction of ICAM 1 expression on bladder tumours by BCG immunotherapy. J Clin Pathol (1994) 0.89
Expression of adhesion molecules by bladder cancer cells: modulation by interferon-gamma and tumour necrosis factor-alpha. J Urol (1992) 0.88
The inhibitory effects of interferon gamma on the growth of bladder cancer cells. J Urol (1992) 0.86
Interleukin-2 production during intravesical bacille Calmette-Guerin therapy for bladder cancer. Clin Immunol Immunopathol (1986) 0.86
Expression and shedding of ICAM-1 in bladder cancer and its immunotherapy. Int J Cancer (1993) 0.86
Local immune responses after intravesical BCG treatment for carcinoma in situ. Br J Urol (1987) 0.84
Stimulating influence of bacillus Calmette-Guérin on immunity to polyoma tumors and spontaneous leukemia. J Natl Cancer Inst (1971) 0.84
Intercellular adhesion molecule-1 expression by bladder cancer cells: functional effects. J Urol (1994) 0.83
The immunomodulatory effects of urine from patients with superficial bladder cancer receiving intravesical evans BCG therapy. Cancer Immunol Immunother (1993) 0.83
Presence of interleukin-2 in urine of superficial bladder cancer patients after intravesical treatment with bacillus Calmette-Guérin. Cancer Immunol Immunother (1990) 0.83
An efficient immunization protocol for production of monoclonal antibodies against soluble human insulin. Immunol Lett (1994) 0.81
Intravesical Bacillus Calmette-Guérin treatment for superficial bladder cancer: results after 15 years of experience. Anticancer Res (1991) 0.80
The genome sequence of Schizosaccharomyces pombe. Nature (2002) 14.26
The genome of the social amoeba Dictyostelium discoideum. Nature (2005) 9.18
BioJava: an open-source framework for bioinformatics. Bioinformatics (2008) 6.17
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst (2000) 5.62
Results of conservative management of clinically localized prostate cancer. N Engl J Med (1994) 5.04
Time to end softly softly approach on harvesting organs for transplantation. Br Med J (Clin Res Ed) (1988) 4.01
Concentration of antibacterial agents in interstitial tissue fluid. Br Med J (1973) 3.09
Anti-lymphocytic antibody--a review. Clin Exp Immunol (1967) 2.75
Pathophysiology of tissue fluid. Proc R Soc Med (1972) 2.46
BCG immunotherapy of bladder cancer: 20 years on. Lancet (1999) 2.38
Human monoclonal antibody production. Current status and future prospects. J Immunol Methods (1987) 2.21
Possible airborne spread of serum-hepatitis virus within a haemodialysis unit. Lancet (1971) 2.14
Laboratory staff qualifications and accuracy of proficiency test results. A national study. Arch Pathol Lab Med (1992) 2.07
The effect of pH on release of PGE2 from vaginal and endocervical preparations for induction of labour: an in-vitro study. Br J Obstet Gynaecol (1992) 2.02
The natural history of Peyronie's disease. J Urol (1990) 2.02
A case for synchronous reduction of testicular androgen, adrenal androgen and prolactin for the treatment of advanced carcinoma of the prostate. Eur J Cancer (1995) 1.92
Effect of antilymphocytic antibody and antibody fragments on human lymphocytes in vitro. Nature (1967) 1.89
Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Prostate (1996) 1.85
EAACI food allergy and anaphylaxis guidelines. Primary prevention of food allergy. Allergy (2014) 1.80
Psychotic men remanded in custody to Brixton Prison. Br J Psychiatry (1994) 1.77
Emergence of early region 1-containing replication-competent adenovirus in stocks of replication-defective adenovirus recombinants (delta E1 + delta E3) during multiple passages in 293 cells. Hum Gene Ther (1994) 1.74
The ecology of adolescent activity and experience. J Youth Adolesc (1977) 1.74
Circadian variation of lymphocyte subpopulations: a study with monoclonal antibodies. Br Med J (Clin Res Ed) (1983) 1.72
Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int J Gynecol Cancer (2003) 1.70
Small-caliber skeletal muscle fibers do not suffer necrosis in mdx mouse dystrophy. Muscle Nerve (1988) 1.67
Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy. J Urol (1990) 1.66
Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol (1999) 1.63
The natural history of renal carcinoma. Semin Oncol (1983) 1.60
The diagnosis of rejection of renal allotransplants in man. Lancet (1969) 1.59
A genomewide suppressor and enhancer analysis of cdc13-1 reveals varied cellular processes influencing telomere capping in Saccharomyces cerevisiae. Genetics (2008) 1.58
T.N.M. classification for urological tumours (U.I.C.C.) - 1974. Br J Urol (1975) 1.57
Some factors influencing the ability of anti-lymphocytic antibody to suppress humoral antibody formation. Clin Exp Immunol (1967) 1.52
Function and health status outcomes in a randomized trial comparing preoperative and postoperative radiotherapy in extremity soft tissue sarcoma. J Clin Oncol (2002) 1.50
The preparation and properties of anti-lymphocytic sera. Prog Surg (1969) 1.48
[Surgical treatment of the single non traumatic perforation of small bowel: excision-suture or resection-anastomosis]. Ann Chir (2005) 1.45
Melatonin administration can entrain the free-running circadian system of blind subjects. J Endocrinol (2000) 1.43
Measurement by radioimmunoassay of prostaglandins as their methyl oximes. Prostaglandins Leukot Med (1986) 1.43
Structure-property correlations in a combinatorial library of degradable biomaterials. J Biomed Mater Res (1998) 1.42
Continuous thoracic epidural analgesia versus combined spinal/thoracic epidural analgesia on pain, pulmonary function and the metabolic response following colonic resection. Acta Anaesthesiol Scand (1996) 1.42
Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med (2016) 1.41
Effect of antilymphocytic antibody and antibody fragments on skin-homograft survival and the blood-lymphocyte count in rats. Lancet (1967) 1.41
Effect of anti-rat lymphocyte antibody on humoral antibody formation. Nature (1967) 1.40
Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol (1992) 1.38
An integrated haematuria clinic. Br J Clin Pract (1993) 1.36
Prostaglandin synthesis in the endometrium of women with ovular dysfunctional uterine bleeding. Br J Obstet Gynaecol (1981) 1.34
Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (1996) 1.32
Hypercalcaemia from calcium ion-exchange resin in patients on regular haemodialysis. Lancet (1968) 1.30
Factors influencing early function of cadaver renal transplants. Lancet (1969) 1.28
Characterization of antilymphocytic antibody. Nature (1967) 1.27
Quality-adjusted time without symptoms or toxicity analysis of interferon maintenance in multiple myeloma. J Clin Oncol (1998) 1.27
Characterization of symptomatic and asymptomatic carotid plaques using high-resolution real-time ultrasonography. Br J Surg (1993) 1.26
The distribution and possible significance of cells identified in human lymphoid tissue by the monoclonal antibody HNK-1. Clin Exp Immunol (1983) 1.25
Multiple organ damage caused by a new toxin azaspiracid, isolated from mussels produced in Ireland. Toxicon (2000) 1.23
Uncommon benign intrascrotal tumours. Ann Acad Med Singapore (2004) 1.23
New allele at cholinesterase locus 1. J Med Genet (1976) 1.20
Lymphography and pelvic lymphadenectomy in carcinoma of the prostate. Br J Urol (1976) 1.20
Fibroblast heterogeneity: existence of functionally distinct Thy 1(+) and Thy 1(-) human female reproductive tract fibroblasts. Am J Pathol (2001) 1.18
Normal and pathological serum levels of alpha2-macroglobulins in men and mice. J Clin Pathol (1975) 1.18
A meta-analysis of local anesthesia for transrectal ultrasound-guided biopsy of the prostate. Prostate Cancer Prostatic Dis (2007) 1.17
Role of inflammatory mediators in human endometrium during progesterone withdrawal and early pregnancy. J Clin Endocrinol Metab (1999) 1.17
Prolongation of canine renal allograft survival with antilymphocytic serum. Transplantation (1968) 1.16
Cytokine secretion by human fetal membranes, decidua and placenta at term. Hum Reprod (1998) 1.16
Postoperative urinary retention in general surgical patients. Br J Surg (1988) 1.15
The effect of anti-lymphocytic antibody on the humoral immune response in different strains of mice. I. The response to bovine serum albumin. Immunology (1972) 1.15
The catheterized patient undergoing transurethral resection of the prostate: a survey of the current practice of British urologists. BJU Int (2003) 1.14
The systemic effects of malignant renal tumours. Br J Urol (1971) 1.14
Dystrophin expression in muscles of mdx mice after adenovirus-mediated in vivo gene transfer. Hum Gene Ther (1996) 1.14
Flexible eating and flexible insulin dosing in patients with diabetes: Results of an intensive self-management course. Diabetes Res Clin Pract (2008) 1.13
Quantitative studies with antilymphocytic antibody. Nature (1967) 1.13
The dose, distribution, and excretion of gentamicin with speical reference to renal failure. J Infect Dis (1969) 1.11
The antecedents of violence and aggression within psychiatric in-patient settings. Acta Psychiatr Scand (2012) 1.10
Studies on a unique diagnostic serum globulin in papular mucinosis (lichen myxedematosus). Clin Exp Immunol (1967) 1.10
Intussusception: a surgical condition. J R Coll Surg Edinb (1988) 1.09
Lipid peroxidation and prostaglandins in colorectal cancer. Br J Surg (1994) 1.09
The catalytic cycle of cytochrome P-450scc and intermediates in the conversion of cholesterol to pregnenolone. Eur J Biochem (1984) 1.08
Presence of secretory leukocyte protease inhibitor in human endometrium and first trimester decidua suggests an antibacterial protective role. Mol Hum Reprod (2000) 1.08
Collagenase versus placebo in the treatment of Peyronie's disease: a double-blind study. J Urol (1993) 1.08
Binding of C-reactive protein to human lymphocytes. II. Interaction with a subset of cells bearing the Fc receptor. J Immunol (1981) 1.08
Hypertension in patients on regular haemodialysis and after renal allotransplantation. Lancet (1969) 1.08
Age, and size and grade of tumour predict prognosis in incidentally diagnosed carcinoma of the prostate. Br J Urol (1988) 1.08
Prevalence and patterns of spina bifida occulta in 2707 normal adults. Clin Radiol (1987) 1.08
A single injection method for measurement of effective renal plasma flow. Br J Urol (1968) 1.08
Expression of natural antimicrobials by human placenta and fetal membranes. Placenta (2006) 1.07
The endocrinology of menstruation--a role for the immune system. Clin Endocrinol (Oxf) (2001) 1.07
Preliminary observations on the effect of heterologous anti-lymphocytic globulin on autologous immune complex nephritis in rats. Clin Exp Immunol (1969) 1.06
Serum testosterone and dihydrotestosterone changes with age in rat. Steroids (1975) 1.06
Gastric mucosal prostaglandin synthesis in the presence of Campylobacter pylori in patients with gastric ulcers and non-ulcer dyspepsia. Am J Gastroenterol (1990) 1.06
Mechanisms of action of intravesical bacille Calmette-Guérin: local immune mechanisms. Clin Infect Dis (2000) 1.06
Basaloid carcinoma of the prostate gland: histogenesis and review of the literature. Histopathology (1992) 1.06
Innate immune defences in the human uterus during pregnancy. Placenta (2007) 1.05
Binding of C-reactive protein to human lymphocytes. I. Requirement for a binding specificity. J Immunol (1981) 1.05
Transient immunosuppression by FK506 permits a sustained high-level dystrophin expression after adenovirus-mediated dystrophin minigene transfer to skeletal muscles of adult dystrophic (mdx) mice. Gene Ther (1996) 1.05
Distribution of fatty and fibrous plaques in young human coronary arteries. Atherosclerosis (1982) 1.05
Dose-response relationship for risk of non-vertebral fracture with inhaled corticosteroids. Clin Exp Allergy (2008) 1.05
Role for CD40-CD40 ligand interactions in the immune response to solid tumours. Mol Immunol (2000) 1.05
Dietary linoleic acid, gastric acid, and prostaglandin secretion. Gastroenterology (1988) 1.05